Mylan's story relates to NPH...Mylan is IMO the most successful US generics co and if NPH wants a big picture "role model" this would be it...there are some good similarities already... Its very interesting that Mylan has picked the country of India in a big way to stake its futre: Mylan has made a huge investment in India in both Manufacturing and marketing... they as of just recently have 12000 workers (over half of their total work force) in India and have recently spent billions of investment there... It is interesting that Mylan sees India as both the best manufacturing location for generics drugs in the world, but even more interesting maybe , they see India as the best future market to sell generics into, in the world .... Also note Mylan has operations in 140 countries, but many of those would be tiny operations I assume...but not India.. Mylan and other analysts see India (and emerging markets in general) as big opportunities because :a) populations are huge, b) incomes too small for brand drugs, c) and incomes are rising fast increasing the percentage of population that can afford generics... Remeber there is lots of room for competition, and NPH is already based in India ... I think the first inning may be just about to start...